Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212

Journal of Clinical Investigation

Volumn 111, Issue 8, 2003, Pages 1231-1240

  Croxford, J Ludovic ^a   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DEMYELINATION; DRUG EFFECT; FEMALE; IMMUNOREGULATION; MACROPHAGE ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RELAPSE; STRAIN DIFFERENCE; VIRUS INFECTION;

ANIMALS; BRAIN; CARDIOVIRUS INFECTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE ACTIVATION; MICE; MORPHOLINES; MULTIPLE SCLEROSIS; MYELIN PROTEOLIPID PROTEIN; NAPHTHALENES; PEPTIDE FRAGMENTS; RNA, MESSENGER; TETRAHYDROCANNABINOL; THEILOVIRUS; VIRAL LOAD;

EID: 0037397037     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317652     Document Type: Article

References (56)

1. Ota, K., et al. 1990. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 346:183-187.
2. Goodin, D.S., et al. 2002. Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 58:169-178.
3. Devane, W.A., Dysarz, F.A., III, Johnson, M.R., Melvin, L.S., and Howlett, A.C. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:605-613.
4. Munro, S., Thomas, K.L., and Abushaar, M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:61-65.
5. Galiegue, S., et al. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:54-61.
6. Klein, T.W., Newton, C., and Friedman, H. 1998. Cannabinoid receptors and immunity. Immunol. Today. 19:373-381.
7. Croxford, J.L. 2003. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 17:179-202.
8. Baker, D., et al. 2001. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:300-302.
9. Baker, D., et al. 2000. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:84-87.
10. Olson, J.K., Croxford, J.L., and Miller, S.D. 2001. Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T cell-mediated autoimmune diseases. Viral Immunol. 14:227-250.
11. Kurtzke, J.F. 1993. Epidemiologic evidence for multiple sclerosis as an infection. Clin. Microbiol. Rev. 6:382-427.
12. Pevear, D.C., Calenoff, M., Rozhon, E., and Lipton, H.L. 1987. Analysis of the complete nucleotide sequence of the picornavirus Theiler's murine encephalomyelitis virus indicates that it is closely related to cardioviruses. J. Virol. 61:1507-1516.
13. Lipton, H.L. 1975. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect. Immun. 11:1147-1155.
14. Miller, S.D., and Gerety, S.J. 1990. Immunologic aspects of Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. Semin. Virol. 1:263-272.
15. Karpus, W.J., Pope, J.G., Peterson, J.D., Dal Canto, M.C., and Miller, S.D. 1995. Inhibition of Theiler's virus-mediated demyelination by peripheral immune tolerance induction. Immunol. 155:947-957.
16. Miller, S.D., et al. 1997. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3:1133-1136.
17. Croxford, J.L., et al. 1998. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol. 160:5181-5187.
18. Croxford, J.L., et al. 2000. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J. Immunol. 164:2776-2781.
19. Croxford, J.L., Feldmann, M., Chernajovsky, Y., and Baker, D. 2001. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 166:4124-4130.
20. Olson, J.K., Eagar, T.N., and Miller, S.D. 2002. Functional activation of myelin-specific T cells by virus-induced molecular mimicry. J. Immunol. 169:2719-2726.
21. Begolka, W.S., Vanderlugt, C.L., Rahbe, S.M., and Miller, S.D. 1998. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol 161:4437-4446.
22. Killestein, J., et al. 2002. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 58:1404-1407.
23. Jacobs, C.A., et al. 1991. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J. Immunol. 146:2983-2989.
24. Samoilova, E.B., Horton, J.L., Hilliard, B., Liu, T.S., and Chen, Y. 1998. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreacrive T cells. J. Immunol. 161:6480-6486.
25. Selmaj, K., Raine, C.S., and Cross, A.H. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:694-700.
26. Qi, Y., and Dal, C.M. 1996. Effect of Theiler's murine encephalomyelitis virus and cytokines on cultured oligodendrocytes and astrocytes. J. Neurosci. Res. 45:364-374.
27. Matias, I., et al. 2002. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur. J. Biochem. 269:3771-3778.
28. Yuan, M., et al. 2002. Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 133:124-131.
29. Molina-Holgado, F., Molina-Holgado, E., and Guaza, C. 1998. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 433:139-142.
30. Molina-Holgado, F., Lledo, A., and Guaza, C. 1997. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport. 8:1929-1933.
31. Sanjabi, S., Hoffmann, A., Liou, H.C., Baltimore, D., and Smale, S.T. 2000. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc. Natl. Acad. Sci. U. S. A. 97:12705-12710.
32. Newton, C.A., Klein, T.W., and Friedman, H. 1994. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect. Immun. 62:4015-4020.
33. Rowell, J.F., and Griffin, D.E. 1999. The inflammatory response to nonfatal Sindbis virus infection of the nervous system is more severe in SJL than in BALB/c mice and is associated with low levels of IL-4 mRNA and high levels of IL-10-producing CD4+ T cells. J. Immunol. 162:1624-1632.
34. Strle, K., et al. 2001. Interleukin-10 in the brain. Crit Rev. Immunol. 21:427-449.
35. Weidenfeld, J., Feldman, S., and Mechoulam, R. 1994. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:110-112.
36. Klein, T.W., Friedman, H., and Specter, S. 1998. Marijuana, immunity and infection. J. Neuroimmunol. 83:102-115.
37. Parolaro, D. 1999. Presence and functional regulation of cannabinoid receptors in immune cells Life Sci. 65:637-644.
38. Noe, S.N., Newton, C., Widen, R., Friedman, H., and Klein, T.W. 2000. Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. J. Neuroimmunol. 110:161-167.
39. Cabral, G.A., Lockmuller, J.C., and Mishkin, E.M. 1986. Delta 9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc. Soc. Exp. Biol. Med. 181:305-311.
40. Trottier, M., Kallio, P., Wang, W., and Lipton, HL. 2001. High numbers of viral RNA copies in the central nervous system of mice during persistent infection with Theiler's virus. J. Virol. 75:7420-7428.
41. Wirguin, I., et al. 1994. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology. 28:209-214.
42. Lyman, W.D., Sonett, J.R., Brosnan, C.F., Elkin, R., and Bornstein, M.B. 1989. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23:73-81.
43. Achiron, A., Miron, S., Lavie, V., Margalit, R., and Biegon, A. 2000. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. 102:26-31.
44. Malfait, A.M., et al. 2000. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 97:9561-9566.
45. Ahmed, Z., et al. 2002. A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis: inflammation versus degeneration. Am. J. Pathol. 161:1577-1586.
46. Hisahara, S., Yuan, J., Momoi, T., Okano, H., and Miura, M. 2001. Caspase-11 mediates oligodendrocyte cell death and pathogenesis of, autoimmune-mediated demyelination. J. Exp. Med. 193:111-122.
47. Molina-Holgado, E., et al. 2002. Cannabinoids promote oligodendrocyte progenitor survival: involvement ofcannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22:9742-9753.
48. Hampson, A.J., Grimaldi, M., Axelrod, J., and Wink, D. 1998. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U. S. A. 95:8268-8273.
49. Werner, P., Pitt, D., and Raine, C.S. 2000. Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in multiple sclerosis? J. Neural Transm. Suppl. 60:375-385.
50. MacLennan, S.J., Reynen, P.H., Kwan, J., and Bonhaus, D.W. 1998. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. 124:619-622.
51. Bouaboula, M., et al. 1997. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272:22330-22339.
52. Berrendero, F., et al. 2001. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 41:195-202.
53. Brooks, J.W., et al. 2002. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol. 439:83-92.
54. Agurell, S, et al. 1986. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38:21-43.
55. McPartland, J.M., and Pruitt, P.L. 1999. Side effects of pharmaceuticals not elicited by comparable herbal medicines: the case of tetrahydroqcannabinol and marijuana. Altern. Ther. Health Meal. 5:57-62.
56. Chan, H.S., Correia, J.A., and MacLeod, S.M. 1987. Nabilone versus prochlorpetazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics. 79:946-952.